Mapatumumab - Human Genome Sciences
Alternative Names: Death-receptor-4-monoclonal-antibody; DR4 mAB; DR4-monoclonal-antibody; HGS-1012; HGS-ETR1; TRAIL-R1 monoclonal antibody; TRAIL-receptor-1-monoclonal-antibody; TRM-1Latest Information Update: 15 Apr 2021
At a glance
- Originator Cambridge Antibody Technology
- Developer Human Genome Sciences
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; TNF-related apoptosis-inducing ligand stimulants; TRAIL receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cervical cancer
- Discontinued Colorectal cancer; Liver cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer
Most Recent Events
- 15 Apr 2021 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Monotherapy) in Canada (IV)
- 15 Apr 2021 Discontinued - Phase-II for Colorectal cancer (Monotherapy) in Germany (IV)
- 15 Apr 2021 Discontinued - Phase-II for Liver cancer (Combination therapy, First-line therapy, Late-stage disease) in Ukraine, Russia, Romania, Puerto Rico, Poland, Germany, USA (IV)